الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 126 |  |  |
| | | from | 126 | | |
Abstract
Aim of the work
The aim of our study is a comparative study between recombinant human erythropoietin and nandrolone decanoate for the treatment of anemia of chronic renal failure patients.
Conclusions
In our study, we have found that after 6 months of therapy, the increase in the hemoglobin concentration obtained in both groups was significant as compared to the basal values, but with a lower economic cost in the androgen group. However, the 6 month hemoglobin level was higher in the erythropoietin group as compared to the androgen group and the rate of rise of hemoglobin concentration is more rapid.
In addition to the erythropoitic action, androgens had beneficial anabolic effects as evidenced by the increase in the serum albumin and dry body weight.
The main side effect of androgens was a rise in the serum concentration of triglycerides. This increment was reversible and disappeared 3 months after the withdrawal of the drug and not considered as an independent risk factor for vascular mortality neither in general population nor in hemodialysis patients.
Liver dysfunctions with abnormal liver function tests, cholestatic hepatits, peliosis hepatitis and hepatocellular carcinoma have been reported in patients receiving 17-alkylated androgens and not nandrolone which is a 19-nortestosterone derivative.